Navigation Links
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.
Date:3/6/2013

NEW YORK, March 6, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Impax Laboratories Inc. ("Impax" or the "Company") (NasdaqGS: IPXL). The investigation focuses on whether the Company and its executives violated federal securities laws.

On March 4, 2013, Shares of Impax dropped $4.10, or 20.5 percent, to $15.90 in aftermarket trading following the Company's announcement that the FDA issued a new Form 483 with twelve observations, three of which are designated as repeat observations from past inspections. New and pending applications that relate to the Hayward, California manufacturing facility may be withheld by the FDA until the Form 483 problems are solved. The FDA sent Impax a warning letter in January 2011 based on an inspection of the Hayward, Calif., plant, and found other problems in a March 2012 inspection. The March 2012 inspection, the FDA said the original problems had been addressed, but it found problems in its quality control laboratory. Shares of Impax stock were down over 25% in early trading on March 5, 2013 from its prior days close. 

If you are aware of any facts relating to this investigation, or purchased shares of Impax, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email eitan@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman , 212-697-6484
eitan@bgandg.com


'/>"/>
SOURCE Bronstein, Gewirtz & Grossman, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza Pharmaceuticals Inc.
2. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
5. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
6. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
7. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
8. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
9. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
10. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
11. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... , July 13, 2017  New York City-based market research ... markets should be aware of.  From new products to new ... detailed in a recently completed study, Potential Pipeline Disruptors ... 1.  Age-Driven Growth - True ... been aware of the impact the growing population and, to ...
(Date:7/11/2017)...  Bayer has awarded grants totaling more than $2 million ... prestigious Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians and ... and Uniformed Services University of the Health Sciences in ... recipients were announced last night during a reception at the ... Berlin, Germany . ...
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... has agreed to schedule an End-of-Phase II meeting with ... its oral insulin capsule ORMD-0801 in the treatment of ... and secondary endpoints by indicating a statistically significant lowering ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... July 26, 2017 , ... A major challenge many labs face is ... samples and a lengthy freeze dry cycle are a few common challenges that can ... as well as new accessories and advancements in laboratory freeze dryers that will improve ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... host its 2017 Process Validation and Process Validation Statistics Conferences in Bethesda, ... process validation lifecycle challenges faced by process validation professionals and statisticians today. ...
(Date:7/26/2017)... ... 26, 2017 , ... Team Type 1 Foundation, a nonprofit organization pursuing a ... diabetes, is excited to announce the 106 college athletes with type 1 diabetes who ... 2005, the Team Type 1 Foundation has bestowed a total of 271 college scholarships ...
(Date:7/26/2017)... ... , ... IDC-Eating Disorder Care is excited to announce Dr. Tracey ... Oak, Michigan. IDC, formerly known as Inner Door Center, was acquired in ... in the field of eating disorder treatment in the state of Michigan. ...
(Date:7/26/2017)... ... ... Wendy M. Musielak, a partner at the Andrew Cores Family Law Group, ... Vice President earlier this year. She will serve the membership in this capacity for a ... accordance with the organization’s by-laws. , Musielak joined the Andrew Cores Family ...
Breaking Medicine News(10 mins):